BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-25 out of 70 found
  Current Search:  gaucher: 70, disease: 5702     

HTML
71%
Frost & Sullivan: Will Big Pharma Embrace its Orphans?
- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007-2012.

The industry is...

Bionity.com:  Nov 21 2008 3:38AM
Matching: gaucher
Find similar documents
HTML
100%
ASHG 2008: Gaucher Disease Mutation Carriers at Higher Risk for Parkinson's Disease
_ ASHG 2008: Gaucher Disease Mutation Carriers at Higher Risk for Parkinson's Disease.
Abstracts in Hematology and Oncology:  Nov 19 2008 9:03PM
Matching: gaucher disease
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0B worth of ethical molecules will come off patent during 2007-2012.

The industry is therefore...

Pharmaceutical Online:  Nov 18 2008 6:25AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
/PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007-2012.

The...

Therapeutics Daily:  Nov 18 2008 4:49AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
/PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007-2012.

The...

Pharma Live:  Nov 18 2008 2:30AM
Matching: gaucher
Find similar documents
HTML
100%
Eight-year Clinical Outcomes Of Enzyme Replacement Therapy In 884 Children With Type I Gaucher Disease
ScienceDaily (Nov.

16, 2008) Gaucher disease is a rare genetic disorder that occurs when a person lacks an enzyme called glucocerebrosidase.

The most common form of this disorder is type 1 Gaucher disease.

Type 1 Gaucher...

Science Daily:  Nov 17 2008 2:36AM
Matching: gaucher disease
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

KLFY:  Nov 17 2008 12:11PM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

Business Journal of Milwaukee:  Nov 17 2008 10:53AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

San Francisco Business Times:  Nov 17 2008 10:46AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion Orphan drugs are intended for the prevention and treatment...

NewsBlaze:  Nov 17 2008 10:45AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

Macro World Investor:  Nov 17 2008 10:32AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

KSLA:  Nov 17 2008 10:29AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

Portland Business Journal:  Nov 17 2008 10:27AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
/PRNewswire via COMTEX/ -- FRSU | Quote | Chart | News | PowerRating -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical...
TradingMarkets:  Nov 17 2008 10:25AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
/PRNewswire via COMTEX/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007-2012.
MarketWatch:  Nov 17 2008 10:25AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

San Antonio Business Journal:  Nov 17 2008 10:25AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

The Business Journal Phoenix:  Nov 17 2008 10:23AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

Biz Journals:  Nov 17 2008 10:19AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
Orphan drugs are intended for the prevention and treatment of very serious rare diseases such as chronic myeloid leukaemia, pulmonary arterial hypertension, gaucher disease and adrenal cortical carcinoma.

Frost & Sullivan (http:/...

Columbus Business First:  Nov 17 2008 10:17AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

Atlanta Business Chronicle:  Nov 17 2008 10:17AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

Globe Investor:  Nov 17 2008 10:15AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

Nashville Business Journal:  Nov 17 2008 10:14AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

Cincinnati Business Journal:  Nov 17 2008 10:13AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

Yahoo! Canada:  Nov 17 2008 10:10AM
Matching: gaucher
Find similar documents
HTML
71%
Will Big Pharma Embrace Its Orphans?
LONDON, Nov.

17 /PRNewswire/ -- While most big pharmaceutical and biotechnology companies have traditionally depended on blockbuster molecules, it is estimated that $90.0 billion worth of ethical molecules will come off patent during 2007...

Calibre Macro World:  Nov 17 2008 10:04AM
Matching: gaucher
Find similar documents

  Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997- - BioPortfolio Limited.